ADMA Biologics (NASDAQ:ADMA) Sees Strong Trading Volume – Here’s What Happened

ADMA Biologics Inc (NASDAQ:ADMA) saw an uptick in trading volume on Wednesday . 7,005,279 shares traded hands during trading, an increase of 105% from the previous session’s volume of 3,412,795 shares.The stock last traded at $9.5370 and had previously closed at $11.33.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Wall Street Zen upgraded shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a report on Tuesday, December 23rd. Finally, Zacks Research raised shares of ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 2nd. Two investment analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $32.00.

ADMA Biologics Stock Down 11.2%

The business has a fifty day moving average of $16.12 and a 200 day moving average of $16.57. The stock has a market cap of $2.40 billion, a price-to-earnings ratio of 16.73 and a beta of 0.51. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.71 and a quick ratio of 3.74.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.20. The firm had revenue of $139.16 million during the quarter, compared to analysts’ expectations of $139.80 million. ADMA Biologics had a net margin of 28.80% and a return on equity of 37.52%. The company’s revenue was up 18.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.46 earnings per share. On average, equities analysts predict that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, Director Steve Elms acquired 7,000 shares of ADMA Biologics stock in a transaction that occurred on Thursday, March 5th. The stock was acquired at an average price of $15.67 per share, with a total value of $109,690.00. Following the purchase, the director owned 2,038,730 shares in the company, valued at approximately $31,946,899.10. This trade represents a 0.34% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the company’s stock in a transaction on Monday, March 9th. The stock was sold at an average price of $15.63, for a total transaction of $157,800.48. Following the completion of the sale, the chief operating officer owned 466,600 shares of the company’s stock, valued at $7,292,958. This represents a 2.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 3.70% of the stock is currently owned by insiders.

Institutional Trading of ADMA Biologics

Several large investors have recently made changes to their positions in ADMA. Salomon & Ludwin LLC acquired a new position in shares of ADMA Biologics during the 3rd quarter valued at about $25,000. Rothschild Investment LLC lifted its holdings in ADMA Biologics by 373.8% in the 3rd quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,495 shares during the last quarter. Summit Securities Group LLC bought a new stake in ADMA Biologics during the fourth quarter worth approximately $29,000. Clearstead Advisors LLC boosted its position in ADMA Biologics by 55.7% during the third quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 795 shares during the period. Finally, iSAM Funds UK Ltd acquired a new position in ADMA Biologics during the third quarter valued at approximately $34,000. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.